1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Pharnext
  6. News
  7. Summary
    ALPHA   FR0011191287

PHARNEXT

(ALPHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Pharnext Names New Chair, Shares Surge 12%

12/23/2021 | 03:37am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
FAURECIA SE 2.41% 24.21 Real-time Quote.-43.49%
PHARNEXT 0.00% 0.0109 Real-time Quote.-93.94%
All news about PHARNEXT
05/16New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in ..
GL
05/16De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de P..
GL
05/16De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de P..
AQ
05/16New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in ..
AQ
05/16Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of..
CI
05/05PHARNEXT : The Latest Findings From CMT&Me, a ?Real-World? Digital Lifestyle Study on Char..
EQ
04/25PHARNEXT : Présentation Corporate de Pharnext
PU
04/25PHARNEXT : Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates
EQ
04/25PHARNEXT : Annual results
CO
03/31Pharnext's Chair Quits; Names Interim Successor
MT
More news
Financials
Sales 2021 3,59 M 3,83 M 3,83 M
Net income 2021 -26,0 M -27,8 M -27,8 M
Net cash 2021 6,83 M 7,29 M 7,29 M
P/E ratio 2021 -0,01x
Yield 2021 -
Capitalization 0,23 M 0,25 M 0,25 M
EV / Sales 2021 -1,84x
EV / Sales 2022 1,71x
Nbr of Employees -
Free-Float 49,7%
Chart PHARNEXT
Duration : Period :
Pharnext Technical Analysis Chart | ALPHA | FR0011191287 | MarketScreener
Technical analysis trends PHARNEXT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,01 €
Average target price 2,50 €
Spread / Average Target 22 836%
EPS Revisions
Managers and Directors
David Horn Solomon Chief Executive Officer & Director
Valérie Worrall Chief Financial Officer
Joshua Schafer Chairman
Philippe Rinaudo Chief Data Science Officer
Burkhard Blank Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PHARNEXT-93.94%0
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530